Beyond the prescription: how GLP-1 Companion digital programs address persistence to medication and Postcessation weight regain. New paper highlights the need for integrated digital behavioral support, proposing a "habit window hypothesis" and associated research agenda to maximize the long-term success of GLP-1 therapies. Newswise - (Toronto, September 9, 2026) Glucagon-like peptide-1 (GLP-1) medications have revolutionized weight management, yet high dropout rates and rapid weight regain remain significant hurdles for many patients. A new viewpoint paper published in the Journal of Medical Internet Research by JMIR Publications highlights a fundamental challenge: medication alone is not enough to secure long-term behavioral change. In the paper titled "Digital Behavioral Infrastructure for Glucagon-Like Peptide-1 Pharmacotherapy: Viewpoint on Persistence, Tolerability, and Postcessation Durability," the author argues that while these drugs effectively target biological appetite, they do not inherently instill the lifestyle routines required to maintain health. To bridge this gap, the paper introduces a "digital behavioral infrastructure" - a theory-driven approach that leverages digital health apps as essential structural companions, helping patients build sustainable habits during the medication's peak efficacy window. The paper maps how two well-validated theories of behavior change, social cognitive theory and behavioral economics, can be leveraged to drive medication persistence, side-effect mitigation, and durable weight loss. Geoff Cook, CEO of Noom, a leading behavior change company, suggests an idea called the "habit window." By dialing down constant food cravings, described by patients as "food noise," GLP-1 drugs free up mental energy, opening a unique opportunity for patients to build healthier daily routines. He also proposes that GLP-1 therapy, when combined with behavioral support, may spark lifestyle change via the "Fresh Start" effect. Digital companion programs use targeted strategies to address the three biggest hurdles of GLP-1 therapy. Personalized digital reminders can help patients stay consistent with their medication, while interactive symptom management features can help reduce gastrointestinal side effects so patients do not quit early. Finally, structured skill-building can help users establish sustainable eating and exercise routines before biological appetite cues return to baseline when treatment stops. "Given the high rate of GLP-1 discontinuation," said Cook, "the objective becomes building healthy behaviors while the habit window is pharmacologically open. While the habit window is a hypothesis, the features suggested in the paper are not theoretical. In fact, these features are part of the Noom app today, as this is exactly how we've built Noom's GLP-1 Companion to take advantage of fast and slow thinking, system 1 and system 2. Most exciting of all is we will be supporting the research program outlined in Table 1 of the paper with RCTs to shed light on the problems, mechanisms, and interventions raised in the paper." While early observational data shows promising results, the paper stresses that prospective, randomized trials are needed to fully test the "habit window" framework. Ultimately, pairing biological appetite control with digital behavioral coaching could mark the difference between temporary weight loss and a lifetime of improved health. Please cite as: Cook G. Digital Behavioral Infrastructure for Glucagon-Like Peptide-1 Pharmacotherapy: Viewpoint on Persistence, Tolerability, and Postcessation Durability J Med Internet Res 2026;28:e104227 About Noom Noom is the leading behavior change company, empowering everyone, everywhere to live better longer - every day. Noom pairs sustainable behavior change with prescription-grade catalysts to make lasting change feel easy. Noom Health partners with top health plans and employers to offer millions of Americans a suite of metabolic health solutions - including Noom Clinical (Noom Med, Noom SmartRx, and NoomRx programs), Noom Weight, Noom Diabetes, and Noom Diabetes Prevention Program. Noom is building the future of preventive care and longevity medicine, leading the convergence of wearable-monitored behavior change, clinical care, diagnostics, and pharmacy into an integrated, AI-enhanced system that drives individualized, meaningful health outcomes. Noom has received multiple grants from the NIH for digital health research and innovation and has been recognized by the CDC for its groundbreaking diabetes prevention programs. Headquartered in Princeton, NJ and with additional offices in New York City, Noom has been recognized as a TIME100 Industry Leader, on Newsweek's Most Trusted Brands list, and it's GLP-1 Companion Program has been recognized by U.S. News & World Reports as "Best for Supplemental Support" in its 2026 ranking of the Best GLP-1 Telehealth Companies. Learn more at noom.com, subscribe to our blog, or follow us on Twitter and LinkedIn. About JMIR Publications JMIR Publications is a leading open access publisher of digital health research and a champion of open science. With a focus on author advocacy and research amplification, JMIR Publications partners with researchers to advance their careers and maximize the impact of their work. As a technology organization with publishing at its core, we provide innovative tools and resources that go beyond traditional publishing, supporting researchers at every step of the dissemination process. Our portfolio features a range of peer-reviewed journals, including the renowned Journal of Medical Internet Research. To learn more about JMIR Publications, please visit jmirpublications.com or connect with us via X, LinkedIn, YouTube, Facebook, Bluesky, and Instagram. Head office: 130 Queens Quay East, Unit 1100, Toronto, ON, M5A 0P6 Canada Media contact: [email protected] The content of this communication is licensed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, published by JMIR Publications, is properly cited. Media contact. Citations. Journal of Medical Internet Research Method of research: Commentary/editorial Subject of research: People Highlights: Peer-Reviewed Download PDF. Type of article. Section.

Solera Health adds Noom to its Weight Management network, expanding digital-first options for members. Partnership brings CDC Full Plus-recognized diabetes prevention program and a no-cost GLP-1 Companion offering to Solera's curated network, in addition to its Noom Weight offering. PHOENIX, Sept. 01, 2026 (GLOBE NEWSWIRE) - Solera Health, the premier digital health delivery company creating flexible solutions to seamlessly connect people to on-benefit care via health plans and employers, today announced the addition of Noom as the newest digital health partner in its Weight Management network. Effective today, Noom brings two evidence-based programs to Solera's network: Noom Weight and the CDC Full Plus-recognized Diabetes Prevention Program (DPP), along with a GLP-1 Companion program included at no extra cost to members. Solera is proud to welcome Noom to its network, a partnership that pairs Noom's proven science-backed approach to behavior change with Solera's commitment to measurable, lasting outcomes. Noom joins Solera's Weight Management lineup, which spans non-clinical programs such as intensive behavioral counseling and the Diabetes Prevention Program, as well as clinical support, adding a fully self-guided, app-based option for members who prefer digital-first support over in-person formats. Grounded in cognitive behavioral therapy, Noom's approach helps members build durable habits around food, activity, and behavioral triggers, giving Solera's network an evidence-backed, pay-for-performance solution that aligns with its outcomes-first approach to care. Proven Results, Backed by Science Noom's DPP also holds CDC Full Plus recognition, the highest level of CDC approval available for diabetes prevention programs. That designation reflects the strongest evidence for participant engagement, retention and outcomes among CDC-recognized programs, and it helps joint customers meet MSSP, ACA and employer preventive care compliance standards. Published outcomes from Noom's programs include*: * 82% of Noom Weight members lose 5% or more of their body weight at one year * 64% of DPP participants prevent or delay the onset of Type 2 diabetes * $1,219 to $5,341 in average member healthcare savings over two years, across the two programs * A 0.28% average A1C reduction among DPP program completers Noom's approach is grounded in cognitive behavioral therapy rather than caloric restriction or meal plans. Its evidence base is supported by more than 50 peer-reviewed publications, a level of clinical scrutiny few consumer health apps undergo. That rigor has translated into a strong member retention record relative to traditional fitness apps. "Every addition to our network must clear a high bar, and Noom has done so with its strength of evidence," said Kris Heinzen, Chief Product Officer at Solera Health. "The beauty of this integration is how it fits into the broader network architecture, where the right program finds the right person without adding another vendor relationship for health plans and employers to manage. That's the whole premise of our curated network: choice without complexity." "Health plans and employers want proven results without adding another vendor to manage, and that's exactly what Solera's network delivers," said Cody Fair, Chief Commercial Officer at Noom. "Being included alongside a CDC Full Plus-recognized DPP and a no-cost GLP-1 Companion means members get evidence-based support exactly when they need it - whether they're managing their weight, preventing diabetes, or navigating a GLP-1 prescription." Solera's matching algorithm handles program selection, and the quiz itself is built member-first, with simple, low-friction questions that make it easy to complete. Once matched, members move directly into the Noom program experience. * Source: Noom internal data and studies. About Solera Health Solera Health delivers a managed, performance-based digital health network purpose-built for health plans and their employer clients. Its curated network of 30-plus clinically validated digital health programs - including CDC-recognized programs - spans eight chronic condition categories - including behavioral health, diabetes, MSK, and weight management - and operates on a pay-for-performance, claims-based billing model that aligns program cost with clinical results. The Solera HALO Platform intelligently matches members to best-fit interventions and integrates directly into health plan operations. For more information, visit soleranetwork.com. About Noom Noom is the leading behavior change company, empowering everyone, everywhere to live better longer - every day. Noom pairs sustainable behavior change with prescription-grade catalysts to make lasting change feel easy. Noom Health partners with top health plans and employers to offer millions of Americans a suite of metabolic health solutions - including Noom Med, Noom Weight, Noom Diabetes, and Noom Diabetes Prevention Program. Noom is building the future of preventive care and longevity medicine, leading the convergence of wearable-monitored behavior change, clinical care, diagnostics, and pharmacy into an integrated, AI-enhanced system that drives individualized, meaningful health outcomes. Noom has received multiple grants from the NIH for digital health research and innovation and has been recognized by the CDC for its groundbreaking diabetes prevention programs. With offices in New York City and Princeton, NJ, Noom has been recognized as a TIME100 Industry Leader, on Newsweek's Most Trusted Brands list, as well as by Inc. and Fortune as a best place to work. Learn more at noom.com, subscribe to our blog, or follow us on Twitter and LinkedIn.

Noom appoints Jim Bugden Chief Financial Officer as company enters next phase of growth. Aug 18, 2026 | Last updated Aug 19, 2026 Source references. Financial and operational leader with deep experience scaling high-growth technology companies joins Noom to support the company's continued expansion. PRINCETON, NJ - August 18, 2026 - Noom, the leading behavior change company, today announced that Jim Bugden has been named Chief Financial Officer. In this role, Bugden oversees Noom's global financial strategy and operations, supporting the company's continued expansion as it builds its comprehensive prescription-grade wellness platform. "Jim brings exactly the financial and operational leadership that Noom needs at this stage of our growth," said Geoff Cook, CEO of Noom. "He has spent his career building the financial infrastructure that allows companies to scale efficiently through periods of complex growth and operational integration. As we expand into new categories and continue to build out our clinical platform, having Jim at the helm of our finance organization is a major advantage." Bugden brings extensive experience leading financial strategy at high-growth technology and consumer companies. Prior to Noom, he served as Chief Financial Officer and Vice President of Video for The Meet Group, a leading social discovery and live-streaming video company. He served as CFO throughout The Meet Group's time as a publicly traded, NASDAQ-listed company, through its 2020 sale to ProSieben, managing significant periods of growth and leading four acquisitions in addition to the sale itself. Bugden has held additional financial and operational leadership roles across a range of businesses, building deep expertise in scaling operations, managing growth, fundraising, and special transactions, including mergers and acquisitions. He served as CFO in Residence at First Round Capital, one of the leading seed-stage venture capital firms, where he advised early-stage founders on building the financial and operational foundations for growth. Bugden also served as CFO of Solve Media, and previously held the position SVP of Corporate Development and Partnerships at Noom. "Noom is at an exciting inflection point," said Bugden. "We're expanding our clinical platform, entering new product categories, and deepening our engagement and relationships with members across the full spectrum of health. I'm proud to join Noom's already strong leadership bench at this moment and look forward to building the financial infrastructure that supports the Company's growth." About Noom: Noom is the leading behavior change company, empowering everyone, everywhere to live better longer - every day. Noom pairs sustainable behavior change with prescription-grade catalysts to make lasting change feel easy. Noom Health partners with top health plans and employers to offer millions of Americans a suite of metabolic health solutions - including Noom Clinical (Noom Med, Noom SmartRx, and NoomRx programs), Noom Weight, Noom Diabetes, and Noom Diabetes Prevention Program. Noom is building the future of preventive care and longevity medicine, leading the convergence of wearable-monitored behavior change, clinical care, diagnostics, and pharmacy into an integrated, AI-enhanced system that drives individualized, meaningful health outcomes. Noom has received multiple grants from the NIH for digital health research and innovation and has been recognized by the CDC for its groundbreaking diabetes prevention programs. Headquartered in Princeton, NJ and with additional offices in New York City, Noom has been recognized as a TIME100 Industry Leader, on Newsweek's Most Trusted Brands list, as well as by Inc. and Fortune as a best place to work. Learn more at noom.com, subscribe to its blog, or follow Noom, Inc. on Twitter and LinkedIn.